Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + Tislelizumab vs Chemotherapy + Tislelizumab in 1L Extensive-stage Small Cell Lung Cancer (PANKU-Lung07)
NCT07502300Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07502300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502300.